New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Highly Regulated (List I)

DERISE

25µG/0,42ML/Injectable Solution/DARBEPOETINE ALFA
HETERO LABS
ManufacturerVerified lab

HETERO LABS

Public retail price
N/ADZD

Identification

Active ingredient (INN)
DARBEPOETINE ALFA
Internal code
12 L 174
Country of Origin
India
Pharmaceutical form
Injectable Solution
Prescription List
Highly Regulated (List I)
Packaging
b/1 serin pre rempli de 0.42 ml
DERISE
Clinical View
Highly Regulated (List I)

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Description

Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD).

Produced in

Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Indications

For the treatment of anemia (from renal transplants or certain HIV treatment)

Pharmacodynamics

Darbepoetin alfa is used in the treatment of anemia.

It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.

Adverse Effects

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Alternatives